

5th August 2023

- | | |
|---|--|
| <p>(1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg</p> | |

Dear Sir/Madam,

Sub: Update on USFDA inspection at Cipla's manufacturing facility in Pithampur, Indore

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to our intimation dated 18th February 2023 on the routine current Good Manufacturing Practices (cGMP) inspection at our Pithampur manufacturing facility, we wish to inform you that the Company has received a communication dated 4th August, 2023 US Time (5th August, 2023 IST) from the United States Food and Drug Administration (USFDA) that the inspection classification of the said facility is Official Action Indicated (“OAI”) as the establishment has not met regulatory requirements and may be subject to further regulatory action. The OAI status may cause delay/withholding of pending product approvals.

We do not see material risk to our existing commercial product portfolio. The Company is in the process of executing de-risking plan for its new products.

The Company will work closely with the USFDA and is committed to address these within the stipulated time.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode